ETrade Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

ETrade Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$340K	Buy	2,418 +1,074	+80%	+$163K	0.01%	680
2020 Q2	$215K	Sell	1,344 -732	-35%	-$99.6K	﹤0.01%	758
2020 Q1	$203K	Sell	2,076 -1,284	-38%	-$147K	0.01%	687
2019 Q4	$434K	Sell	3,360 -199	-6%	-$20.1K	0.01%	590
2019 Q3	$268K	Buy	3,559 +452	+15%	+$53.4K	0.01%	710
2019 Q2	$472K	Buy	3,107 +153	+5%	+$18.6K	0.01%	579
2019 Q1	$352K	Sell	2,954 -1,321	-31%	-$170K	0.01%	636
2018 Q4	$467K	Sell	4,275 -238	-5%	-$29.8K	0.02%	502
2018 Q3	$729K	Buy	4,513 +76	+2%	+$10.4K	0.02%	462
2018 Q2	$586K	Buy	4,437 +474	+12%	+$44.7K	0.02%	493
2018 Q1	$294K	Sell	3,963 -471	-11%	-$31.4K	0.01%	631
2017 Q4	$247K	Buy	+4,434	New	+$235K	0.01%	667

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ETrade Capital Management's SRPT Position: Q3 2020 in Review

ETrade Capital Management increased its Sarepta Therapeutics (SRPT) stake by 80% in Q3 2020, buying an estimated $163K and bringing the position to 2,418 shares worth $340K. The position accounts for 0.01% of the portfolio, ranked #680.

ETrade Capital Management first reported a position in SRPT in Q4 2017 and has held it in 12 quarters since. The position peaked at $729K in Q3 2018. 404 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

ETrade Capital Management held 2,418 shares of Sarepta Therapeutics worth $340K as of Q3 2020.
ETrade Capital Management bought 1,074 Sarepta Therapeutics shares in Q3 2020, an estimated $163K.
Sarepta Therapeutics made up 0.01% of ETrade Capital Management's portfolio in Q3 2020, its #680 holding.
ETrade Capital Management first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 12 quarters since.
ETrade Capital Management's Sarepta Therapeutics position peaked at $729K in Q3 2018.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.